| Calistoga Pharmaceuticals, Inc. is currently developing multiple compounds selectively targeting the phosphoinositide-3 kinase (PI3K) pathway, a pathway known to be involved in certain cancers and inflammatory diseases. Our approach is to selectively inhibit the delta isoform of the PI3K, a isoform that is expressed in cells of hematopoietic origin. Our initial clinical indications are hematological malignancies and asthma and rheumatoid arthritis. Additionally we are exploring other B-cell diseases which are particularly sensitive to PI3K-delta inhibitors. Our technology assets include broad intellectual property in the delta isoform of PI3K and small molecule inhibitors that selectively target that isoform, as well as a robust pipeline of drug candidates. A Phase 1 trial of CAL-101, an orally available, small molecule inhibitor for inflammatory disease and cancer, is currently underway.
Calistoga Pharmaceuticals was founded in 2006 by Michael Gallatin, PhD, Neill Giese, PhD, and Roger Ulrich, PhD. In 2007, Daryl Winter, PhD, JD and Albert Yu, MD were added to the executive team as COO and CMO respectively. We have raised more than $25 million from well respected venture investors in life sciences including Frazier Healthcare Ventures, Alta Partners, Three Arch Partners and Amgen Ventures. Calistoga Pharmaceuticals is a privately held organization headquartered in Seattle, Washington. |
